Why Some People Don't Feel Edibles
Why oral THC fails for some users and what the evidence says.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
People genuinely report feeling nothing from edibles at doses that affect others strongly. The real causes are: low bioavailability (you absorb 4–20% of what you eat), genetic variants in liver enzymes that change 11-hydroxy-THC production, mislabeled products, and tolerance from other routes. We don't fully understand why some individuals remain non-responders despite ruling these out.
Plain-Language Summary
Some people eat a 10 mg cannabis edible, wait hours, and feel nothing — while others at the same dose report strong effects. Reports from cannabis users and clinicians describe a subset who consistently experience little or no effect from oral THC at doses that work well for others Weak / limited[1].
Four main explanations exist, in rough order of how well supported they are:
- Bioavailability. Your digestive system and liver absorb only 4–20% of swallowed THC. A 10 mg dose might deliver 0.5–2 mg to your brain — a huge difference Strong evidence[2].
- Liver enzyme variants. Genetic differences in CYP2C9 change how much of the active metabolite 11-hydroxy-THC your liver makes Strong evidence[3].
- The product wasn't accurately labeled. Independent testing has found edibles with THC content 50% below or above the label Strong evidence[4].
- Tolerance. Daily cannabis use from any route blunts the response to edibles.
If you have ruled these out and still feel nothing, the reason remains unclear — and anyone claiming they know exactly why is overconfident.
What Probably Explains It: Stronger Evidence
CYP2C9 genetic variation
THC is metabolized in the liver by two main enzymes: CYP2C9 and CYP3A4. CYP2C9 converts THC into 11-hydroxy-THC (11-OH-THC), a metabolite that readily crosses into the brain. In human studies, 11-OH-THC is as potent or more potent than THC itself Strong evidence[3][5].
People carry different genetic variants of CYP2C9. Those with the 3/3 genotype have reduced enzyme activity. In a controlled pharmacokinetic study, 3/3 carriers showed roughly three times higher blood THC exposure and stronger sedation than 1/1 'normal' metabolizers after oral THC Strong evidence[3]. This means slow metabolizers are at risk of over-response, not non-response.
The flip side — that 'ultra-rapid' or normal metabolizers might clear THC so fast that peak effects are minimal — is plausible but more inferred than proven in direct human studies Weak / limited.
First-pass metabolism and bioavailability
When you swallow THC, it passes through the stomach and small intestine, is absorbed into the bloodstream, and travels to the liver before reaching systemic circulation. This first-pass metabolism dramatically reduces how much active drug reaches your brain.
Published bioavailability estimates range from 4% to 20% — meaning you retain only a fraction of the dose you ingest Strong evidence[2][6]. Individual variation in this range is substantial. Two people eating the same 10 mg gummy could end up with effective doses of 0.4 mg and 2 mg respectively.
Product inaccuracy
Multiple laboratory audits in legal cannabis markets have tested edibles against their labels. Results show significant mislabeling: products labeled "10 mg THC" containing anywhere from 4 mg to 16 mg in real testing Strong evidence[4]. If your gummy actually contains 3 mg instead of 10 mg, non-response isn't biology — it's a manufacturing problem.
Fed versus fasted state
THC is highly lipophilic (fat-soluble). Taking an edible with a fatty meal substantially increases absorption compared to an empty stomach, as shown in pharmacokinetic studies of dronabinol (synthetic oral THC) Strong evidence[7]. Conversely, taking an edible on an empty stomach can delay and reduce peak effects.
What Might Explain It: Weaker Evidence
Endocannabinoid tone
The hypothesis: people with naturally high baseline endocannabinoid system activity have downregulated CB1 receptors and respond less to exogenous THC. Preclinical studies and some indirect human data support this idea, but no validated clinical test exists for measuring CB1 receptor density in cannabis non-responders Weak / limited.
Tolerance from other routes
Regular cannabis users — whether smoking, vaping, or dabbing concentrates — develop measurable cannabinoid receptor downregulation that recovers over weeks to months of abstinence Strong evidence[8]. This tolerance applies to edibles too. A person who smokes daily may need a much larger oral dose to feel effects, or may not respond at all until tolerance partially resets.
Gut microbiome
The human microbiome influences the metabolism and bioavailability of many drugs. Speculation exists that microbiome composition affects THC absorption or metabolite production, but as of now there is no published evidence testing this hypothesis in cannabis users No data.
Expectation, setting, and anxiety
Mild psychoactive effects can be obscured by distraction, anxiety, or a neutral mindset. Expectancy effects are well documented in psychoactive drug research Weak / limited. This doesn't mean the effect is "all in your head" — it means that context genuinely alters perception and reportability of subtle effects.
What Does Not Hold Up
Indica vs. sativa edibles. The popular claim that "sativa edibles work for me but indica doesn't" relies on the false assumption that cannabis strain type predicts effect. Once cannabis is decarboxylated and infused into food, the volatile terpene profile — which drove the original sativa/indica folklore — is largely destroyed or transformed Disputed.
Eating mango before edibles. The idea that myrcene from mango increases THC absorption is popular folklore. Controlled human studies testing whether dietary myrcene alters THC effects do not exist No data.
"Your liver is just too strong." This is a casual misinterpretation of pharmacogenomics. There is no such thing as a universally "strong" or "weak" liver — rather, specific enzyme variants change how you metabolize specific drugs, including THC Disputed.
Sublingual absorption of standard edibles. Common gummies and baked goods are formulated for gastrointestinal absorption. Holding them under the tongue does not meaningfully circumvent first-pass metabolism unless the product is specifically designed for oromucosal delivery (tinctures, lozenges, mouthfilms) Weak / limited.
What We Don't Know
- Population prevalence. No large epidemiological study has systematically measured how many cannabis users experience genuine edible non-response after controlling for dose, product accuracy, and tolerance No data.
- CYP3A4 and drug interactions. CYP3A4 is involved in THC metabolism alongside CYP2C9. Whether common CYP3A4 inducers (St. John's Wort, rifampin, certain anticonvulsants) routinely cause clinically significant edible non-response in patients is not well studied Weak / limited.
- Nanoemulsion and fast-acting edibles. Manufacturers market nanoemulsified THC as faster-acting and more bioavailable. Whether these formulations meaningfully reduce variability in absorption or help convert non-responders into responders remains unclear — marketing claims exceed published evidence Weak / limited.
- Receptor-level insensitivity. Whether some individuals have intrinsic insensitivity to 11-OH-THC at the CB1 receptor level (analogous to aspirin non-responders or statin non-responders in other contexts) is an open question.
Medical Alternatives if Edibles Don't Work
For medical patients who do not respond to edibles, clinicians typically consider:
Inhalation (vaporized flower). Bypasses first-pass hepatic metabolism entirely. Onset occurs within minutes; dosing is more predictable than edibles for experienced users. Duration is shorter (2–4 hours vs. 6–12 hours for edibles) Strong evidence[2][6].
Sublingual tinctures and oromucosal sprays. Products like nabiximols (Sativex, where available) partially bypass first-pass metabolism through absorption in the oral mucosa. These typically deliver more consistent effects than standard edibles, though onset is slower than inhalation Strong evidence[9].
Dronabinol (Marinol) or nabilone. FDA-approved synthetic oral THC analogs. They share the same first-pass metabolism issue as cannabis edibles, so non-responders may struggle here too — but standardized dosing and pharmaceutical formulation remove the product-accuracy variable Strong evidence.
Dose titration. For confirmed non-responders not in an acute tolerance state, slow upward titration under clinical guidance remains the standard approach.
None of these approaches should be self-directed if you have cardiovascular disease, a history of psychosis, or take medications that interact with cannabinoids. Consult a qualified clinician.
Risks of Repeated Dosing Without Response
The most common cannabis-related emergency department visit involving edibles is accidental overconsumption: a user feels nothing at 90–120 minutes, assumes the dose was too low, takes a second or third dose, then is hit with the combined load 2–4 hours later Strong evidence[10].
Symptoms of acute THC toxicity include severe anxiety, panic attacks, nausea and vomiting, rapid heart rate (tachycardia), dizziness, confusion, and in rare cases transient psychosis. Most cases resolve within hours without specific treatment, but emergency care is sometimes necessary.
Special risk: If you are a CYP2C9 slow metabolizer (3/3 genotype) who incorrectly assumes you are a non-responder and redoses, the consequences can be severe — that genotype is associated with sustained, intensified THC exposure Strong evidence[3].
Practical approach (not medical advice):
- Always wait at least 2 hours, ideally 3, before taking more.
- Use products from reputable sources with third-party lab testing.
- Take edibles with food.
- Before concluding you are a non-responder, try a tested 20–25 mg dose on two separate occasions.
- If you genuinely don't respond after ruling out dose, accuracy, tolerance, and food effects, talk to a clinician about alternative routes.
> Medical Disclaimer: This article is educational information, not medical advice. Cannabis interacts with many prescription medications including warfarin, clobazam, tacrolimus, and others. Do not start, stop, or change cannabis use without consulting a qualified healthcare provider. Individuals with a history of psychosis, cardiovascular disease, or pregnancy should avoid cannabis.
Sources
- Peer-reviewed Schlienz NJ, Spindle TR, Cone EJ, et al. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug and Alcohol Dependence. 2020;211:107969.
- Peer-reviewed Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. 2003;42(4):327–360.
- Peer-reviewed Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clinical Pharmacology & Therapeutics. 2009;85(3):273–276.
- Peer-reviewed Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491–2493.
- Peer-reviewed Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972;177(4043):62–64.
- Peer-reviewed Huestis MA. Human cannabinoid pharmacokinetics. Chemistry & Biodiversity. 2007;4(8):1770–1804.
- Peer-reviewed Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586–1592.
- Peer-reviewed D'Souza DC, Cortes-Briones JA, Ranganathan M, et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2016;1(1):60–67.
- Peer-reviewed Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clinical Pharmacology & Therapeutics. 2011;89(3):400–407.
- Peer-reviewed Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Annals of Internal Medicine. 2019;170(8):531–537.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and SSRIs — What science shows about mixing cannabis with antidepressant medication.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...
- Why Edibles Hit Different — How first-pass metabolism and 11-hydroxy-THC make oral cannabis distinct from inhalation.